Skip to content
The Policy VaultThe Policy Vault

Rubraca (rucaparib tablets – pharmaand GmbH) — Cigna

Uterine Leiomyosarcoma

Initial criteria

  • Patient age ≥ 18 years
  • Patient has BRCA2-altered disease
  • Patient has tried one systemic regimen

Approval duration

1 year